Cellular Intelligence Company Profile

Background

Overview

Cellular Intelligence, formerly known as Somite AI, is an AI-native TechBio company dedicated to understanding, predicting, and controlling cell behavior. The company is building the first universal virtual cell-signaling model to decode and control the complex language of cells. By leveraging proprietary capsule technology, Cellular Intelligence generates dynamic cellular data at over 1,000 times higher efficiency than existing methods, transforming biology into an engineering discipline.

Mission and Vision

The mission of Cellular Intelligence is to empower life science and biotech innovators with expert insight, strategic guidance, and execution support that accelerate their path from discovery to market. Their vision is to become the global standard in bridging scientific innovation and commercial impact through seamless integration of expertise, insight, and trusted partnerships.

Primary Area of Focus

Cellular Intelligence focuses on developing AI-driven models to predict and control cellular behavior, with applications in regenerative medicine, drug response prediction, and disease mechanism modeling. Their proprietary capsule technology enables the generation of large-scale predictive models, enhancing the effectiveness and efficiency of cell-based treatments.

Industry Significance

By transforming biology into a predictive engineering discipline, Cellular Intelligence addresses the complexities of cell signaling, offering solutions that can accelerate breakthroughs in human health. Their work has the potential to revolutionize regenerative medicine and drug discovery by providing precise control over cell differentiation and function.

Key Strategic Focus

Core Objectives

Develop a universal virtual cell-signaling model to predict cellular responses to external signals.

Utilize AI and capsule technology to generate large-scale, context-rich datasets for training predictive models.

Apply predictive models to design regenerative medicine protocols, predict drug responses, and model disease mechanisms.

Specific Areas of Specialization

AI-driven modeling of cell signaling pathways.

High-throughput experimentation using capsule technology.

Regenerative medicine and cell therapy development.

Key Technologies Utilized

Proprietary capsule-based platform for high-throughput cell-signaling analysis.

Large-scale predictive models trained on extensive cellular datasets.

Advanced computational biology techniques for data analysis and model development.

Primary Markets or Conditions Targeted

Regenerative medicine and cell therapies.

Drug discovery and development.

Disease modeling and understanding disease mechanisms.

Financials and Funding

Funding History

Cellular Intelligence has raised over $62 million to date. In May 2025, the company secured over $47 million in a Series A funding round led by Khosla Ventures, with participation from AMD Ventures, Fusion Fund, and others. This followed a pre-seed round in April 2024, raising $10.3 million from investors including Texas Venture Partners and TechAviv.

Intended Utilization of Capital

The capital raised is intended to accelerate the development of Cellular Intelligence's foundation models for cell therapy, enhance their proprietary capsule technology, and expand their team to support ongoing research and commercialization efforts.

Pipeline Development

Key Pipeline Candidates

Cellular Intelligence is developing the BioBrain Virtual Cell Model, a predictive model of cell state transitions in response to external cues. This model supports in silico protocol design, hypothesis generation, and decision support across differentiation and maturation workflows.

Stages of Clinical Trials or Product Development

As of April 2026, Cellular Intelligence is in the pre-clinical development stage, focusing on refining their predictive models and validating their technology through extensive experimentation.

Target Conditions

The company's technology aims to address a wide range of conditions, including those requiring regenerative medicine and cell therapies, such as diabetes, obesity, and muscular dystrophies.

Relevant Timelines for Anticipated Milestones

Cellular Intelligence has demonstrated significant progress, including scaling their experiments to over 1 million unique experimental conditions, indicating a rapid advancement toward their development goals.

Technological Platform and Innovation

Proprietary Technologies

Capsule-based platform for high-throughput cell-signaling analysis.

BioBrain Virtual Cell Model for predicting cell state transitions.

Significant Scientific Methods

Split-and-pool technique for running millions of unique experiments in parallel.

Active learning loop and data augmentation to refine predictive models.

AI-Driven Capabilities

Large-scale predictive models trained on extensive cellular datasets.

Advanced computational biology techniques for data analysis and model development.

Leadership Team

Key Executive Profiles

Micha Breakstone, Ph.D. – Co-founder and CEO. Repeat AI entrepreneur who previously built and sold Chorus.ai for $575 million.

Jonathan Rosenfeld, Ph.D. – Co-founder and CTO. Leader of MIT's Fundamental AI Group, pioneered AI scaling laws.

Allon Klein, Ph.D. – Scientific Co-founder. HMS Professor; Recipient of National Academy of Sciences James Prize.

Olivier Pourquié, Ph.D. – Scientific Co-founder. HMS/BWH Professor; Member of National Academy of Sciences & National Academy of Medicine.

Arjun Raj, Ph.D. – Head of Computational Biology. Penn Professor; Recipient of NIH Director's New Innovator Award & NIH Director’s Transformative R01 Award.

Cliff Tabin, Ph.D. – Scientific Co-founder. Chair of the HMS Genetics Department; Member of National Academy of Sciences.

Jay Shendure, M.D., Ph.D. – Scientific Co-founder. UW Professor, HHMI investigator; Member of National Academy of Sciences.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in the areas of regenerative medicine and cell therapies, is experiencing rapid growth. Advancements in AI and machine learning are driving innovation, leading to more efficient and effective treatments. Companies like Cellular Intelligence are at the forefront of this transformation, leveraging technology to overcome traditional challenges in cell therapy development.

Competitor Analysis

Cellarity: Focuses on cell-based therapeutics and has developed a platform for cell analysis and drug discovery.

Multiply Labs: Specializes in automated cell therapy manufacturing, aiming to improve the scalability and consistency of cell-based treatments.

Cellino: Utilizes laser-based bioprinting technology to create patient-specific cell therapies.

Strategic Collaborations and Partnerships

Cellular Intelligence has secured strategic investments from AMD Ventures and other notable investors, which support the acceleration of their foundation models for cell therapy.

Operational Insights

Cellular Intelligence's proprietary capsule technology enables high-throughput experimentation, allowing for the testing of millions of signal combinations in parallel. This capability provides a significant competitive advantage in the field of cell therapy development.

Strategic Opportunities and Future Directions

The company is well-positioned to lead in the development of predictive models for cell behavior, with applications in regenerative medicine, drug discovery, and disease modeling. Ongoing advancements in their technology and strategic partnerships are expected to drive future growth and innovation.